The FDA inspection that can end a trial site

Most clinical research professionals will work near an FDA inspection at some point, and many will help prepare for one without fully understanding how it is scored or what is at stake. The program is called Bioresearch Monitoring, or BIMO, and it is how the FDA polices the conduct of clinical trials. Here is the field guide.

Who gets inspected

BIMO inspects the people and organizations that run trials: clinical investigators (the site physicians), sponsors and the CROs that act for them, IRBs (the ethics boards that approve studies), sponsor-investigators (one person acting as both), and bioequivalence facilities. Clinical investigators are by far the largest category, accounting for roughly two-thirds of BIMO inspections. If you work at a site, your PI is the most inspected role in the entire system.

The three-letter grade

Every inspection ends in one of three classifications, and learning them is the key to reading the whole system:

• NAI, no action indicated: nothing objectionable found. The clean result.
• VAI, voluntary action indicated: objectionable conditions were found, but the FDA expects you to fix them voluntarily without formal action. This is the common middling outcome, and dozens to over a hundred inspections land here each year.
• OAI, official action indicated: serious enough to warrant regulatory action, which can mean a warning letter, rejection of the site's data, or in the worst cases disqualification of the investigator.

The important nuance: OAI is rare. For clinical investigators it runs in the single digits per year, and for sponsors and CROs it is close to zero. So the practical enforcement signal is not the rare OAI. It is the VAI bucket and the handful of public warning letters that follow the worst cases.

The count is rising

BIMO inspection volume collapsed during the pandemic and has rebounded hard. Total BIMO inspections went from 766 in fiscal 2022 to 1,073 in fiscal 2023, a sharp recovery as the FDA returned to the field. More inspections means more findings, more remediation work, and more sites and sponsors having to answer for how their trials were run. For the people who staff those trials, a rising inspection count is a rising workload, whether or not any single inspection turns up something serious.

Why it matters to your job

An inspection is not a passive event that happens to a site. Preparing for one, hosting one, and responding to its findings is real work that lands on CRAs, coordinators, quality staff, and the PI. A clean NAI still costs weeks of preparation. A VAI or OAI costs far more, in the remediation that follows. The inspection system is, among other things, a recurring demand on clinical research labor, and understanding how it is scored is the first step to seeing that demand coming.

What the FDA data cannot tell you

The BIMO metrics tell you how many inspections happened and how they were graded. They do not tell you what an inspection did to the people who lived through it: the overtime, the CAPA work, the stress of a for-cause visit, or whether a bad outcome cost anyone their role. Those experiences live with the workers who had them. If you have been through an FDA inspection, that is knowledge the next site could use. Share what you can, and add your datapoint to the survey.